GlassScriptPhysician profile
Shyam A Vyas
NPI 1992850184
$6,357.17
in general payments reported to CMS, 2019-2025
22 companies · $690 in 2025
The $690 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $155 · 2021: $431 · 2022: $412 · 2023: $3,584 · 2024: $317 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Consulting Fee: $1,620 · Travel and Lodging: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.58 |
| Consulting Fee | $1,620.00 |
| Travel and Lodging | $1,051.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $3,275.00 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $909.31 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $347.28 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Abbvie INC. | $251.90 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.67 | 2022-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $222.20 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $202.42 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $182.04 | 2019-2024 | Rexulti |
| Allergan, INC. | $141.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.84 | 2019-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $95.12 | 2019 | |
| Supernus Pharmaceuticals, INC. | $65.87 | 2021-2023 | Qelbree |
| Axsome Therapeutics, INC. | $54.89 | 2025 | Auvelity |
| Shire North American Group INC | $50.47 | 2019 | |
| Lundbeck LLC | $42.58 | 2022-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $37.47 | 2023-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $32.65 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.09 | 2021 | |
| Alkermes, INC. | $22.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.66 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.95 | 2020 | |
| Adlon Therapeutics L.P. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyam Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.